Stocktoria
Elanco Animal Health Inc ELAN
Elanco Animal Health Inc financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B | $3.3B | $3.1B | $3.1B | $2.9B |
| Gross profit | $2.6B | $2.4B | $2.5B | — | — | — | — | — | — |
| R&D expense | $368.0M | $344.0M | $327.0M | $321.0M | $369.0M | $329.0M | $270.0M | $246.6M | $251.7M |
| SG&A expense | $1.4B | $1.3B | $1.3B | $1.3B | $1.4B | $997.0M | $760.0M | $735.2M | $779.8M |
| Interest expense | — | — | $277.0M | $241.0M | $236.0M | $150.0M | $79.0M | $29.6M | $0 |
| Income tax | $8.0M | $150.0M | $36.0M | $6.0M | -$88.0M | -$103.0M | $10.0M | $27.6M | $78.1M |
| Net income | -$232.0M | $338.0M | -$1.2B | -$78.0M | -$483.0M | -$574.0M | $68.0M | $86.5M | -$310.7M |
| EPS (diluted) | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 | $-1.30 | $0.18 | $0.28 | $-1.06 |
| Operating cash flow | $560.0M | $541.0M | $271.0M | $452.0M | $483.0M | -$41.0M | $224.0M | $487.3M | $173.8M |
| Free cash flow | $284.0M | $394.0M | $131.0M | $281.0M | $324.0M | -$176.0M | $84.0M | $352.8M | $75.2M |
| Cash & equivalents | $545.0M | $468.0M | $352.0M | $345.0M | $638.0M | $495.0M | $334.0M | $474.8M | $323.4M |
| Inventory | $1.7B | $1.6B | $1.7B | $1.5B | $1.4B | $1.6B | $1.1B | $1.0B | $1.1B |
| Total assets | $13.4B | $12.6B | $14.4B | $15.5B | $16.5B | $17.7B | $9.0B | $9.0B | $8.9B |
| Total liabilities | $6.8B | $6.5B | $8.1B | $8.2B | $9.0B | $9.2B | $3.4B | $3.8B | $1.2B |
| Shareholders' equity | $6.5B | $6.1B | $6.2B | $7.3B | $7.5B | $8.5B | $5.5B | $5.2B | $7.8B |
Growth · year-over-year · Revenue CAGR 6.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +6.2% | +0.5% | +0.1% | -7.4% | +45.6% | +6.6% | +0.1% | +6.2% | — |
| Net income growth | -168.6% | — | — | — | — | -944.1% | -21.4% | — | — |
| EPS growth | -169.1% | — | — | — | — | -822.2% | -35.7% | — | — |
| Free cash flow growth | -27.9% | +200.8% | -53.4% | -13.3% | — | -309.5% | -76.2% | +369.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.